prikaz prve stranice dokumenta The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy
  Download
PDF 620.08 KB
Scientific paper - Original scientific paper
The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy
Medicina, 58 (2022), 2; 252-266. https://doi.org/10.3390/medicina58020252
Mikolačević, Ivana; Domislović, Viktor; Krznarić- Zrnić, Irena; Krznarić, Zeljko; Virović-Jukić, Lucija; Stojsavljević, Sanja; Grgurević, Ivica; Milić, Sandra; Vukoja, Ivan; Puž, Petra; Aralica, Merica; Hauser, Goran

Cite this document

Mikolačević, I., Domislović, V., Krznarić Zrnić, I., Krznarić, Z., Virović Jukić, L., Stojsavljević, S. ... Hauser, G. (2022). The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina, 58. (2), 252-266. doi: 10.3390/medicina58020252

Mikolačević, Ivana, et al. "The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy." Medicina, vol. 58, no. 2, 2022, pp. 252-266. https://doi.org/10.3390/medicina58020252

Mikolačević, Ivana, Viktor Domislović, Irena Krznarić Zrnić, Zeljko Krznarić, Lucija Virović Jukić, Sanja Stojsavljević, Ivica Grgurević, et al. "The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy." Medicina 58, no. 2 (2022): 252-266. https://doi.org/10.3390/medicina58020252

Mikolačević, I., et al. (2022) 'The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy', Medicina, 58(2), pp. 252-266. doi: 10.3390/medicina58020252

Mikolačević I, Domislović V, Krznarić Zrnić I, Krznarić Z, Virović Jukić L, Stojsavljević S, and sur.. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina [Internet]. 2022 [cited 2024 November 17];58(2):252-266. doi: 10.3390/medicina58020252

I. Mikolačević, et al., "The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy", Medicina, vol. 58, no. 2, pp. 252-266, 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:267:004975. [Accessed: 17 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy
AuthorIvana Mikolačević
AuthorViktor Domislović
AuthorIrena Krznarić- Zrnić
AuthorZeljko Krznarić
MBZ: 75865
AuthorLucija Virović-Jukić
AuthorSanja Stojsavljević
AuthorIvica Grgurević
AuthorSandra Milić
AuthorIvan Vukoja
AuthorPetra Puž
AuthorMerica Aralica
AuthorGoran Hauser
Author's institutionUniversity of Rijeka
Faculty of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background and Objective: This study was conducted to evaluate the diagnostic performance of various biomarkers for steatosis, fibrosis, and inflammation in comparison to a liver biopsy (LB) in patients with nonalcoholic fatty liver disease (NAFLD). Materials and Methods: This was a cross- sectional study that included 135 patients with biopsy-proven NAFLD. Fatty liver index (FLI), hepatic steatosis index (HSI), cell death markers (CK-18 M30 and CK-18 M65), FIB-4 index, NAFLD fibrosis score (NFS), BARD, and AST to platelet ratio index (APRI) were calculated and analysed. Results: FLI, HSI scores, and the cell death biomarkers showed poor diagnostic accuracy for steatosis detection and quantification, with an area under the curve (AUC) of <0.70. The cell death biomarkers likewise did not perform well for the detection of nonalcoholic steatohepatitis (NASH) (AUC < 0.7). As for the fibrosis staging, only APRI and the cell death biomarkers had moderate accuracy (AUC > 0.7) for advanced fibrosis, whereas FIB-4, BARD, and NFS scores demonstrated poor performance (AUC < 0.70). However, a combination of FIB-4 and NFS with the cell death biomarkers had moderate accuracy for advanced (≥F3) fibrosis detection, with an AUC of >0.70. Conclusions: In this first study on Croatian patients with NAFLD, serum biomarkers demonstrated poor diagnostic performance for the noninvasive diagnosis of liver steatosis and NASH. APRI and the cell death biomarkers had only moderate accuracy for diagnosing advanced fibrosis, as did the combination of FIB-4 and NFS with the cell death biomarkers. Further studies regarding serum biomarkers for all NAFLD stages are needed.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleMedicina
Numberingvol. 58, no. 2, pp. 252-266
p-ISSN1648-9144
e-ISSN1010-660X
DOIhttps://doi.org/10.3390/medicina58020252
URN:NBNurn:nbn:hr:267:004975
Publication2022
Document URLhttps://www.mdpi.com/1648-9144/58/2/252/htm
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-03-04 07:09:54